NASDAQ:TNDM - Tandem Diabetes Care Stock Price, Forecast & News

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Shares of Tandem Diabetes Care reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care Inc (NASDAQ:TNDM) released its earnings results on Monday, November, 4th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.07. The medical device company earned $94.66 million during the quarter, compared to the consensus estimate of $88.46 million. Tandem Diabetes Care had a negative return on equity of 9.44% and a negative net margin of 7.19%. View Tandem Diabetes Care's Earnings History.

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Tandem Diabetes Care.

13 analysts have issued 12 month target prices for Tandem Diabetes Care's shares. Their forecasts range from $55.00 to $100.00. On average, they expect Tandem Diabetes Care's share price to reach $75.92 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for Tandem Diabetes Care.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

Media coverage about TNDM stock has trended extremely negative on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tandem Diabetes Care earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Tandem Diabetes Care.

Tandem Diabetes Care saw a increase in short interest in January. As of January 15th, there was short interest totalling 6,970,000 shares, an increase of 17.7% from the December 31st total of 5,920,000 shares. Based on an average trading volume of 1,460,000 shares, the short-interest ratio is presently 4.8 days. Approximately 12.5% of the shares of the stock are sold short. View Tandem Diabetes Care's Current Options Chain.

Some companies that are related to Tandem Diabetes Care include Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), NuVasive (NUVA), Nevro (NVRO), ICU Medical (ICUI), Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS) and Merit Medical Systems (MMSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and Paypal (PYPL).

Tandem Diabetes Care's stock is owned by a number of of retail and institutional investors. Top institutional investors include Columbus Circle Investors (1.12%), Chicago Capital LLC (0.75%), Assenagon Asset Management S.A. (0.03%), Tocqueville Asset Management L.P. (0.02%), Alpha Windward LLC (0.01%) and Campbell & CO Investment Adviser LLC (0.01%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Wedbush Securities Inc., Janney Montgomery Scott LLC and Global Retirement Partners LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

TNDM stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Chicago Capital LLC, Alpha Windward LLC, Campbell & CO Investment Adviser LLC, Tocqueville Asset Management L.P. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $69.10.

Tandem Diabetes Care has a market capitalization of $4.08 billion and generates $183.87 million in revenue each year. The medical device company earns $-122,610,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Tandem Diabetes Care employs 653 workers across the globe.View Additional Information About Tandem Diabetes Care.

The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com/.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]